Results 141 to 150 of about 737 (195)
Some of the next articles are maybe not open access.
Contact sensitization to 6 alpha-methylprednisolone aceponate.
American journal of contact dermatitis : official journal of the American Contact Dermatitis Society, 1997Increasing attention has been focused on contact sensitization to topical corticosteroids in the past several years. In most cases, allergy to topical corticosteroids occurs in patients with long-lasting eczematous diseases. Cross-allergy between topical corticosteroid molecules is very common, and four groups of cross-reacting molecules have been ...
Balato N +4 more
openaire +5 more sources
Allergic contact dermatitis from 6α‐methylprednisolone aceponate and budesonide
Contact Dermatitis, 1998---
CORAZZA, Monica, VIRGILI, Anna
openaire +2 more sources
Structural study of polymorphism in methylprednisolone aceponate
Journal of Molecular Structure, 2017Abstract The crystal structures of methylprednisolone aceponate were determined by X-ray diffraction analysis at temperatures 90 K and 150 K: space group P212121, a = 14.8592(2), b = 19.6844(5), c = 26.1626(4) A, Z = 12; R = 0.0598 (T = 90 K); space group P212121, a = 6.57348(14), b = 14.8295(3), c = 26.2214(5) A, Z = 4; R = 0.0518 (T = 150 K ...
A.V. Knyazev +6 more
openaire +1 more source
Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers
Journal of the American Academy of Dermatology, 1993Many skin diseases respond to topical corticosteroid therapy. The first drug of this class, hydrocortisone, has been succeeded by ever more potent corticosteroids. However, these have a greater potential for systemic and local side effects. I, 2 Aseparation of clinical effects and epidermal thinning was first described with clobetasone butyrate.' which
A, Kecskés +4 more
openaire +2 more sources
Methylprednisolone aceponate for atopic dermatitis
International Journal of Dermatology, 2017AbstractBackgroundThe 4th generation topical corticosteroids (TCS) have demonstrated a most favorablerisk–benefit ratio. Methylprednisolone aceponate (MPA) is a non‐halogenated corticosteroid with a methyl group at C6, which confers higher intrinsic activity.
openaire +2 more sources
Allergic contact dermatitis to methylprednisolone aceponate in a topical corticosteroid
Australasian Journal of Dermatology, 2004SUMMARY A 42‐year‐old registered nurse presented with a recurrent history of multifactorial hand dermatitis, which had ceased to respond to the topical corticosteroid that she was using. Patch testing revealed strong reactions to both Advantan® Fatty Ointment (Commonwealth Serum Laboratories, Melbourne, Australia), and its active ingredient ...
Jennifer, Cahill, Rosemary, Nixon
openaire +2 more sources
Frontiers of rapid itch relief: a review of methylprednisolone aceponate
Journal of the European Academy of Dermatology and Venereology, 2012AbstractIn a paediatric population, the successful management of childhood atopic dermatitis (AD) should include the careful evaluation and selection of available therapies, based not only on demonstrated safety and tolerability in small children and infants, but also on their evidence‐based, anti‐pruritic benefits. Moreover, the speed of anti‐pruritic
L, García Ponte, U, Ebert
openaire +2 more sources
Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate
Journal of the European Academy of Dermatology and Venereology, 1994AbstractObjective: Preclinical characterization of methylprednisolone aceponate.Results: The local antiinflammatory potency of methylprednisolone aceponate was equal to the very strong glucocorticoid clobetasol 17‐propionate but higher than the potency of hydrocortisone 17‐butyrate after topical application in 2 animal models of inflammation ...
H.J. Zentel, M. Töpert
openaire +1 more source
European Journal of Clinical Pharmacology, 1992
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized.
A, Kecskés +4 more
openaire +2 more sources
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized.
A, Kecskés +4 more
openaire +2 more sources
Skin atrophogenic potential of methylprednisolone aceponate (MPA)
Journal of the European Academy of Dermatology and Venereology, 1994AbstractThe most prominent and most discussed local side effect of topical corticosteroids is the thinning of the skin. Therefore, the atrophogenic potential is an important indication of the quality of a new corticosteroid. Several studies have been conducted to investigate this parameter. In rats, the effect of breaking strength of the skin, the most
openaire +1 more source